Annual report pursuant to Section 13 and 15(d)

Parent Company Condensed Statements of Cash Flows

v3.3.1.900
Parent Company Condensed Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Notes      
Adjustments to reconcile net loss to net cash used in operating activities:      
Change in fair value of derivative instruments $ (36,587) $ (12,213)  
Notes | Notes Due February 1, 2033      
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on conversion of 3.00% convertible senior notes (900)    
Parent Company      
Cash flows from operating activities:      
Net loss (30,028) (171,666) $ (114,407)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 85 97 149
Non-cash interest on 2033 Senior Notes 2,612 5,662 5,980
Amortization of deferred financing costs 1,212 2,007 1,170
Losses from investments in investees 7,105 3,587 11,456
(Income) loss from subsidiaries (76,428) 115,561 62,775
Equity-based compensation – employees and non-employees 26,074 14,779 10,983
Revenue from receipt of equity 0 0 (12,740)
Realized gain on sale of equity securities 7,091 167 (29,881)
Gain on conversion of 3.00% convertible senior notes (943) (2,668) (972)
Change in fair value of derivative instruments 39,442 11,019 45,991
Gain on deconsolidation of SciVac (15,940) 0 0
Changes in other assets and liabilities (15,640) (5,627) 2,264
Net cash used in operating activities (55,358) (27,082) (17,232)
Cash flows from investing activities:      
Investments in investees (4,375) (589) (17,441)
Subsidiary financing 62,471 (85,386) (36,151)
Proceeds from sale of equity securities 0 1,331 30,556
Acquisition of businesses, net of cash acquired (138) (231) (300)
Capital expenditures (92) (18) (236)
Net cash provided by (used in) investing activities 57,866 (84,893) (23,572)
Cash flows from financing activities:      
Issuance of 2033 Senior Notes, net, including related parties 0 0 170,184
Payment of Series D dividends, including related parties 0 0 (3,015)
Proceeds from the exercise of Common Stock options and warrants 25,921 12,928 23,425
Net cash provided by financing activities 25,921 12,928 190,594
Net increase (decrease) in cash and cash equivalents 28,429 (99,047) 149,790
Cash and cash equivalents at beginning of period 69,218 168,265 18,475
Cash and cash equivalents at end of period 97,647 69,218 168,265
SUPPLEMENTAL INFORMATION:      
Interest paid 2,175 3,686 2,640
RXi common stock received 0 0 12,500
Pharmsynthez common stock received 0 6,264 0
Non-cash financing:      
Shares issued upon the conversion of Common Stock options and warrants, surrendered in net exercise 14,369 3,494 815
Parent Company | Bio-Reference Laboratories, Inc.      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 950,148 0 0
Parent Company | EirGen Pharma Limited      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 33,569 0 0
Parent Company | OPKO Biologics      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 0 586,643
Parent Company | OPKO Renal      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 20,113 21,155 146,902
Parent Company | OPKO Brazil      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 0 436
Parent Company | OPKO Health Europe      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 1,813 0 4,404
Parent Company | OPKO Uruguay Ltda.      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 159 0
Parent Company | Inspiro      
Issuance of capital stock to acquire or contingent consideration settlement:      
Capital stock issued 0 8,566 0
Parent Company | Conversion of Series D Preferred Stock      
Non-cash financing:      
Shares issued, amount 0 0 24,386
Parent Company | Conversion of Senior Notes      
Non-cash financing:      
Shares issued, amount $ 120,299 $ 95,665 $ 20,839